Journal Article

DKFZ-2017-01635

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.

Betge, J. (First author)DKFZ* ; Barat, A. ; Murphy, V. ; Hielscher, T.DKFZ* ; Van Grieken, N. C. ; Belle, S. ; Zhan, T.DKFZ* ; Härtel, N. ; Kripp, M. ; Bacon, O. ; Cordes, M. ; Kay, E. W. ; Verheul, H. M. W. ; Neerincx, M. ; Hennessy, B. ; Hofheinz, R. D. ; Gaiser, T. ; Ylstra, B. ; Prehn, J. H. M. ; Lambrechts, D. ; Byrne, A. T. ; Ebert, M. P. ; Schulte, N.

2016
Karger Basel

This record in other databases:

Please use a persistent id in citations: doi:10.1159/000449412

Abstract: This study is aimed at analyzing the survival rates and prognostic factors of stage IV colorectal cancer patients from 3 European cohorts undergoing combination chemotherapy with bevacizumab.Progression free-survival (PFS) and overall survival (OS) were analyzed in 172 patients using the Kaplan-Meier method and uni- and multivariable Cox proportional hazards regression models.The median PFS was 9.7 and the median OS 27.4 months. Patients treated at centers in Germany (n = 97), Ireland (n = 32), and The Netherlands (n = 43) showed a median PFS of 9.9, 9.2, and 9.7 months, OS of 34.0, 20.5, and 25.1 months, respectively. Patients >65 years had a significantly shorter PFS (9.5 vs. 9.8 months) but not OS (27.4 vs. 27.5 months) than younger patients. High tumor grade (G3/4) was associated with a shorter PFS, T4 classification with both shorter PFS and OS. Fluoropyrimidine (FP) chemotherapy backbones (doublets and single) had comparable outcomes, while patients not receiving FP backbones had a shorter PFS. In multivariable analysis, age and non-FP backbone were associated with inferior PFS, T4 classification and therapy line >2nd were significantly associated with poor PFS and OS.The observed survival rates confirm previous studies and demonstrate reproducible benefits of combination bevacizumab regimens. Classification T4, non-FP chemotherapy backbone, and age >65 were associated with inferior outcome.

Keyword(s): Angiogenesis Inhibitors ; Pyrimidines ; Bevacizumab ; 5-fluoropyrimidine

---

Contributing Institute(s):

1. Biostatistik (C060)
2. Signalwege und Funktionelle Genomik (B110)

Research Program(s):

1. 312 - Functional and structural genomics (POF3-312) (POF3-312)

Appears in the scientific report 2016

---

Database coverage:
; Allianz-Lizenz / DFG ; BIOSIS Previews ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---